LSE - Delayed Quote GBp

Smith & Nephew plc (SN.L)

983.40 -1.40 (-0.14%)
At close: April 24 at 4:35 PM GMT+1

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.
NameTitlePayExercisedYear Born
Dr. Deepak S. Nath Ph.D. CEO & Director 3.74M -- 1972
Mr. John Terence Rogers CFO & Executive Director -- -- 1969
Mr. Paul Connolly President of Global Operations -- -- 1968
Mr. Andrew Swift Vice President of Investor Relations -- -- --
Ms. Helen Barraclough Group General Counsel & Company Secretary -- -- 1979
Ms. Alison Parkes Chief Compliance Officer & Compliance APAC -- -- 1972
Mr. Joe Metzger Senior Vice President of Marketing Services & Communications -- -- --
Mr. Philip G. Cowdy Chief Corporate Development & Corporate Affairs Officer -- -- 1967
Ms. Elga Lohler Chief Human Resources Officer -- -- 1968
Dr. Vasant Padmanabhan Ph.D. President of Research & Development and Ear, Nose & Throat -- -- 1967

Smith & Nephew plc

Building 5
Croxley Park Hatters Lane
Watford, WD18 8YE
United Kingdom
44 1923 477 100 https://www.smith-nephew.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
18,452

Description

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Corporate Governance

Smith & Nephew plc’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 8; Board: 2; Shareholder Rights: 1; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Mar 28, 2024
    Ex-Dividend Date

Upcoming Events

Feb 27, 2024
Smith & Nephew plc Earnings Call

Related Tickers